Changeflow GovPing Pharma & Drug Safety Solid Lipid Nanoparticle Curcumin Formulation P...
Routine Notice Added Final

Solid Lipid Nanoparticle Curcumin Formulation Patent Granted

Favicon for changeflow.com USPTO Patent Grants - Pharma (A61K)
Published
Detected
Email

Summary

USPTO granted Patent US12599572B2 to Punjab University Chandigarh on April 14, 2026, covering solid lipid nanoparticle formulations of curcumin with particle sizes of 20-800 nm and entrapment efficiency of 50-100%. The patent, filed November 26, 2019, contains 20 claims for a process of preparing and compositions of the nanoparticles showing increased curcumin efficacy.

What changed

USPTO issued Patent US12599572B2 to Punjab University Chandigarh, granting exclusivity for solid lipid nanoparticle curcumin formulations. The patent covers particles sized 20-800 nm with high entrapment efficiency (50-100%) and a process for preparing the nanoparticles. The patent was filed November 26, 2019, and contains 20 claims.

For pharmaceutical companies and researchers in drug delivery, this patent establishes intellectual property barriers for similar solid lipid nanoparticle curcumin formulations in the US market. Parties developing competing products should evaluate potential licensing needs or design-around strategies to avoid infringement.

What to do next

  1. Monitor for updates

Archived snapshot

Apr 14, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Solid lipid nanoparticles of curcumin

Grant US12599572B2 Kind: B2 Apr 14, 2026

Assignee

Punjab University Chandigarh

Inventors

Indu Pal Kaur, Vandita Kakkar, Simarjot Kaur Sandhu, Tanvi Gupta

Abstract

Provided herein is a process for preparing solid lipid nanoparticles of curcumin. Also provided herein are solid lipid nanoparticles of curcumin having a particle size in the range of 20-800 nm. The solid lipid nanoparticles of curcumin show a very high entrapment efficiency of curcumin in the range of 50-100% in terms of actual curcumin content of the formulation. The solid lipid nanoparticles of curcumin show increased efficacy of the curcumin.

CPC Classifications

A61K 9/5123 A61K 9/5192 A61K 31/12 A61K 36/9066 A61K 9/51 B82Y 5/00

Filing Date

2019-11-26

Application No.

17439617

Claims

20

View original document →

Get daily alerts for USPTO Patent Grants - Pharma (A61K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 14th, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US12599572B2

Who this affects

Applies to
Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing 3254.1 Biotechnology
Activity scope
Patent licensing IP registration Pharmaceutical R&D
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Public Health Healthcare

Get alerts for this source

We'll email you when USPTO Patent Grants - Pharma (A61K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!